HGH Fragment 176-191
Also known as: HGH Frag 176-191, Frag 176-191
HGH Fragment 176-191 is a fragment of human growth hormone studied in research settings for effects on fat metabolism. It is not approved for human use in Australia and is treated as a research compound.
- Category
- Metabolic / Fat Loss
- Reported half-life
- Not well established
- Common forms
- Research-grade lyophilised powder (not approved), Research-grade vials (not approved)
- Research status
- A growth-hormone fragment studied in research contexts. Not approved for human use in Australia; treated as a research-only compound.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported in research to be investigated for fat-breakdown effects
- Reported to act on fat metabolism without the blood-sugar effects associated with full growth hormone
- Reported to be studied as the basis for modified analogues
How it is reported to work
HGH Fragment 176-191 represents the C-terminal portion of the human growth hormone molecule. It is proposed to stimulate the breakdown of fat (lipolysis) while reportedly avoiding some of the broader effects of complete growth hormone. These mechanisms are reported from research and are not established in an approved therapy.
Background
HGH Fragment 176-191 is a fragment of the human growth hormone molecule that has been examined in research for effects on fat metabolism. It is not approved for human use in Australia and is treated as a research-only compound. This page is educational and is not medical advice; it does not recommend use.
What the research shows
This fragment is reported in laboratory and animal research to be of interest for fat breakdown. These are reported research findings, not established outcomes in people, and robust human clinical evidence is lacking.
| Feature | Reported in research |
|---|---|
| Origin | C-terminal hGH fragment |
| Reported focus | Fat metabolism |
| Approval | Not approved for human use |
What people use it for (reported)
In online discussion, HGH Fragment 176-191 is reported to be of interest for fat-loss goals because of its relationship to growth hormone. As an unapproved research compound, it has no approved human indication in Australia. Material described online as “Frag 176-191” is not a verified, approved product, so its identity, purity and contents cannot be assumed, which is why independent testing is discussed in this community.
Things to be aware of
Because this fragment is unapproved for human use, its long-term safety is not established, and the limited reported effects may not reflect what is sold informally. Reported effects on this page are not confirmed facts; they summarise what research and discussion describe. Anyone with weight or metabolic concerns should consult a qualified healthcare professional for individualised guidance. This article is educational, does not recommend any dose, and does not tell anyone to obtain or use it.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported interest in stimulating fat breakdown (lipolysis)
- Reported to act on fat metabolism without the blood-sugar effects linked to full growth hormone
- Reported not to raise IGF-1 the way complete growth hormone is said to
- Reported as the basis for modified fat-loss analogues
Common side effects
- Injection-site redness or irritation reported
- Headache reported by some users
- Flushing or transient warmth reported
- Fatigue reported
Rare / serious side effects
- Allergic or hypersensitivity reactions reported
- Unverified effects from contaminated grey-market product
- Unknown long-term endocrine effects
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of HGH Fragment 176-191. Listed so you can make an informed decision, not to suggest any use is safe.
- Reported use of unverified research-grade product despite no approved human use
- Reported stacking with growth hormone or secretagogues to amplify fat loss without oversight
- Reported dosing above research amounts seeking faster body-composition change
- Reported substitution for medical weight management
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Any reported fat-loss effects are described as gradual, building over weeks to months rather than rapidly.
First effects
Subtle appetite or energy shifts reported in the first week or two
Noticeable change
Reported gradual fat-loss support with diet and training
Clear results
Reported body-composition changes over months
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take HGH Fragment 176-191. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous injection |
|---|---|
| Typical reported dose | Reported as roughly 250-500 mcg per dose |
| Frequency | Reported as 2-3 times daily, or as a single dose before fasted cardio |
| Cycle length | Reported in multi-week blocks alongside diet and training; no standardised cycle exists |
Reported reconstitution (mg → units)
A 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL. A 250 mcg (0.25 mg) dose is about 0.1 mL = 10 units on a U-100 insulin syringe.
Work out the units for your vial → CalculatorCommonly reported as daily subcutaneous use over multi-week blocks alongside diet and exercise; reported patterns are inconsistent and not standardised. This is reported information, not advice.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Reported combined with GH secretagogues toward fat-loss goals
Reported paired for GH-axis support alongside fat metabolism
Reported discussed together as related GH-fragment fat-loss compounds
Safety notes
HGH Fragment 176-191 is not approved for human use in Australia and its long-term safety in humans is not established. Reported effects come from limited research. Anyone with weight or metabolic questions should consult a qualified healthcare professional rather than relying on unapproved compounds.